Francisco Silva - Feb 18, 2023 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director, 10%+ Owner
Signature
/s/ Francisco Silva
Stock symbol
BRTX
Transactions as of
Feb 18, 2023
Transactions value $
-$1,118
Form type
4
Date filed
2/28/2023, 06:26 AM
Previous filing
Feb 17, 2023
Next filing
Mar 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Tax liability -$1.12K -374 -0.23% $2.99 166K Feb 18, 2023 Direct F1, F2
holding BRTX Common Stock 12.1K Feb 18, 2023 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 1 Feb 18, 2023 Common Stock 1 $3,000.00 Direct F3
holding BRTX Stock Option 3 Feb 18, 2023 Common Stock 3 $3,000.00 Direct F3
holding BRTX Stock Option 1 Feb 18, 2023 Common Stock 1 $3,000.00 Direct
holding BRTX Stock Option 9 Feb 18, 2023 Common Stock 9 $3,000.00 Direct F3
holding BRTX Stock Option 6 Feb 18, 2023 Common Stock 6 $3,000.00 Direct F3
holding BRTX Stock Option 15 Feb 18, 2023 Common Stock 15 $3,000.00 Direct F3
holding BRTX Stock Option 20 Feb 18, 2023 Common Stock 20 $3,000.00 Direct F3
holding BRTX Stock Option 25 Feb 18, 2023 Common Stock 25 $3,000.00 Direct F3
holding BRTX Stock Option 293K Feb 18, 2023 Common Stock 293K $5.08 Direct F4
holding BRTX Stock Option 42.1K Feb 18, 2023 Common Stock 42.1K $5.08 Direct F5
holding BRTX Stock Option 107K Feb 18, 2023 Common Stock 107K $2.91 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were withheld from vested stock grant to pay the associated withholding taxes.
F2 Includes 98,862 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F3 The option is currently exercisable.
F4 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F5 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.
F6 The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 with the remaining 53,381 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested.